AHL
LYRA

Abel Hall LLC’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Abel Hall LLC’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-244
Closed -$1.54K – 308
2025
Q1 		$1.54K Sell
244
-109
-31% -$1.02K ﹤0.01% 202
2024
Q4 		$3.64K Buy
+353
New +$3.88K ﹤0.01% 165

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abel Hall LLC's LYRA Position: Q2 2025 in Review

Abel Hall LLC sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 244 shares — an estimated $1.54K sold.

Abel Hall LLC first reported a position in LYRA in Q4 2024 and held it in 2 quarters. The position peaked at $3.64K in Q4 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • Abel Hall LLC reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Abel Hall LLC sold 244 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $1.54K.
  • Abel Hall LLC first reported a position in LYRA THERAPEUTICS INC in Q4 2024 and held it in 2 quarters.
  • Abel Hall LLC's LYRA THERAPEUTICS INC position peaked at $3.64K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on Abel Hall LLC's 13F filing for Q2 2025, filed 23 Jul 2025.